Irbesartan detailed information

Irbesartan detailed information
Clinical data
[[Regulation of therapeutic goods \|Template:Engvar data]]	EU EMA: by INN; US FDA: Irbesartan;
Pregnancy; category	D (Au);
Routes of; administration	Oral
ATC code	C09CA04 (WHO) ;
Legal status
Legal status	S4 (Au), POM (UK), ℞-only (U.S.);
Pharmacokinetic data
Bioavailability	60–80%
Metabolism	Hepatic (CYP2C9)
Elimination half-life	11–15 hours
Excretion	Renal 20%, faecal 65%
Identifiers
	IUPAC name 2-butyl-; 3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-; 1,3-diazaspiro[4.4]non-1-en-4-one;
CAS Number	138402-11-6;
PubChem CID	3749;
DrugBank	APRD00413;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C25H28N6O
Molar mass	428.53

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

For patient information, click here

Irbesartan (INN) (Template:PronEng) is an angiotensin II receptor antagonist used mainly for the treatment of hypertension. Irbesartan was developed by Sanofi Research (now part of sanofi-aventis). It is jointly marketed by sanofi-aventis and Bristol-Myers Squibb under the trade names Aprovel, Karvea, and Avapro.

Clinical use

Indications

As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of hypertension. Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,^[1] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).^[2]

Combination with diuretic

Irbesartan is also available in a combination formulation with a low dose thiazide diuretic, invariably hydrochlorothiazide, to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including CoAprovel, Karvezide, Avalide and Avapro HCT.

References

↑ Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. (2001). "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes". N Engl J Med. 345 (12): 851–60. PMID 11565517.
↑ Rossi S, editor. Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3